Research groups
Ekta Mukhopadhyay
DPhil
Postdoctoral Researcher in Mucosal Immunology
I am a Post- Doctoral Researcher in mucosal immunology working on pre-clinical evaluation of oral vaccines. I have been involved in vaccine research working on adenoviral (ChAd63 and ChAdOx1) and Virus-like particle vaccines (R21) for infectious diseases like malaria, HIV, influenza and zika. My past experience of working on process development, production and quality assessment of these vaccines made me curious about pre-clinical vaccine development which I was able to study during my DPhil in Clinical Medicine at the Jenner Institute. I have been a part of the Clinical Biomanufacturing Facility team and involved in process development and production of the first batch of the R21 vaccine for the Phase I clinical trial that has now advanced into Phase III trials.
During my DPhil, I have explored and assessed new malaria vaccine candidates for immunogenicity and efficacy that have provided promising results to progress into clinical trials. I have also investigated into alternative vaccination strategies and exploring glycans as malaria vaccine candidates. During this time, I got an opportunity to be a part of the Oxford/AZ ChAdOx1 nCov-19 coronavirus vaccine and R21 vaccine clinical trials.
Recent publications
-
Emulsion and liposome-based adjuvanted R21 vaccine formulations mediate protection against malaria through distinct immune mechanisms.
Journal article
Reinke S. et al, (2023), Cell rep med, 4
-
Production of a high purity, C-tagged hepatitis B surface antigen fusion protein VLP vaccine for malaria expressed in Pichia pastoris under cGMP conditions.
Journal article
Mukhopadhyay E. et al, (2022), Biotechnol bioeng
-
Virus-like particle vaccines
Chapter
Mukhopadhyay E. et al, (2022), Vaccinology and Methods in Vaccine Research, 163 - 176
-
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Journal article
Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993
-
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.
Journal article
Datoo MS. et al, (2021), Lancet, 397, 1809 - 1818
-
Efficacy of a low dose candidate malaria vaccine, R21 in adjuvant Matrix-M™, with seasonal administration to children in Burkina Faso
Journal article
EWER K. et al, (2021), The lancet
-
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Journal article
Voysey M. et al, (2021), Lancet, 397, 881 - 891
-
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Journal article
Barrett JR. et al, (2021), Nat med, 27, 279 - 288
-
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Journal article
Voysey M. et al, (2021), Lancet, 397, 99 - 111
-
Screening of viral-vectored P. falciparum pre-erythrocytic candidate vaccine antigens using chimeric rodent parasites.
Journal article
Kolli SK. et al, (2021), Plos one, 16
-
SAFETY, IMMUNOGENICITY AND DURABILITY OF A NOVEL MALARIA VACCINE CANDIDATE, R21 ADJUVANTED WITH AS01(B)
Conference paper
Venkatraman N. et al, (2017), American journal of tropical medicine and hygiene, 97, 132 - 132
-
SAFETY AND IMMUNOGENICITY OF WITH NOVEL MALARIA VACCINE CANDIDATE, R21 ADJUVANTED WITH MATRIX M1
Other
Venkatraman N. et al, (2017), American journal of tropical medicine and hygiene, 95, 123 - 123